NYSCF Partners With Quris to Accelerate Artificial Intelligence-Fueled Drug Discovery

NYSCF recently began a new partnership with Quris – an artificial intelligence (AI) innovator –  to advance AI-driven strategies for predicting clinical safety and efficacy of drugs. 

Quris uses ‘patient-on-a-chip’ technology, in which nanosensors are used to monitor the responses of patient cells to potential drugs/treatments. The data obtained in this process is analyzed using AI to predict how well these potential drugs will fare in clinical trials.

“Put simply: We are not mice, so what works in animal-based trials is not a proper indicator of what will work for people,” said Aaron Ciechanover, MD, DSc, Chairman of Quris’ Scientific Advisory Board in a press release. “Using a breakthrough way to test drug candidates on miniaturized patients on chips, Quris can demonstrate their safety and efficacy, or lack thereof, through preliminary chip-based clinical trials.”

This new partnership will enable Quris to train its AI using hundreds of stem-cell-derived ‘patients-on-a-chip’ created in collaboration with NYSCF, reflecting the broad genetic diversity of the human population.

“We are at the cusp of a complete paradigm shift in drug testing and development,” noted Susan L. Solomon, JD, Founder and CEO of the NYSCF Research Institute, who is now joining the Quris Advisory Board. “Our team of scientists is excited about the collaboration with Quris, which leverages a powerful synergy between our stem cell automation technology with Quris’ impressive AI-Chip-on-Chip technology platform and team, to better predict clinical safety of drugs for individual patients.” 

Learn more about NYSCF’s work to use AI to uncover new drug targets.

Cover image: Stem cells. Photo credit: Tom Rusielewicz, PhD